ECHOIQ LIMITED — Capital/Financing Update 2026

Apr 7, 2026

FOR IMMEDIATE RELEASE

8 April 2026

S708A Cleansing Notice

==> picture [160 x 148] intentionally omitted <==

Sydney: AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ)) has issued 1,000,000 fully paid ordinary shares (Shares) pursuant to the exercise of unlisted options ($0.35; 20 June 2028).

The Shares are part of a class of securities quoted on the Australian Securities Exchange Limited (ASX).

The Company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act 2001. The Shares were issued without disclosure to the investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act 2001. The Company, as at the date of this notice, has complied with:

• the provisions of Chapter 2M of the Corporations Act 2001; and

• • Section 674 and 674A of the Corporations Act 2001.

There is no excluded information as at the date of this notice, for the purposes of Sections 708A(7) and (8) of the Corporations Act 2001.

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries: Andrew Grover, Executive Chair andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

TM Registered trademark or trademark of Echo IQ Ltd. or its affiliates. © 2025 Echo IQ Ltd. All rights reserved.

Echo IQ Limited ABN 48 142 901 353 U5 | 264 Stirling Hwy Claremont | WA 6010 +61 2 9159 3719 www.echoiq.ai